Novel Therapies in Polycythemia Vera

被引：10

作者：

Tremblay, Douglas ^{[1
]}

Mascarenhas, John ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol Oncol, One Gustave L Levy Pl,Box 1079, New York, NY 10029 USA

来源：

CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2020年 / 15卷 / 02期

关键词：

Polycythemia vera; MDM2; Idasanutlin; Ropeginterferon; Givinostat; Ruxolitinib; ESSENTIAL THROMBOCYTHEMIA; INTERFERON-ALPHA; LOW TOXICITY; OPEN-LABEL; FOLLOW-UP; IN-VITRO; RUXOLITINIB; HYDROXYCARBAMIDE; TRANSFORMATION; COMBINATION;

D O I：

10.1007/s11899-020-00564-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review Polycythemia vera is a myeloproliferative neoplasm characterized by increased erythrocyte count, thrombotic potential, and transformation to myelofibrosis. Older patients and those who have a history of thrombosis require cytoreductive therapy, most commonly with hydroxyurea. Other currently available therapies include pegylated interferon alfa-2a and the JAK1/2 inhibitor ruxolitinib. However, there are limitations to these agents, including potential detrimental adverse effects. In this review, we will describe current therapeutic options for the treatment of PV and then detail new agents with available clinical trial data. Recent Findings A number of novel investigational therapies including MDM2 inhibitors, histone deacetylase inhibitors, and long-acting pegylated interferon alfa-2b are in various stages of clinical development with encouraging efficacy data. The therapeutic landscape for patients with PV is expanding. Novel agents are in development that not only reduce the thrombotic potential but also act directly on the malignant PV clone with the intention of significantly modifying disease progression.

引用

页码：133 / 140

页数：8

共 49 条

[1]

Agency EM, 2019, EU MARKETING AUTHORI

[2] Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea [J].

Alvarez-Larran, Alberto ;

Martinez-Aviles, Luz ;

Carlos Hernandez-Boluda, Juan ;

Ferrer-Marin, Francisca ;

Luisa Antelo, Maria ;

Burgaleta, Carmen ;

Isabel Mata, M. ;

Xicoy, Blanca ;

Martinez-Trillos, Alejandra ;

Teresa Gomez-Casares, M. ;

Antonia Duran, M. ;

Marcote, Barbara ;

Ancochea, Agueda ;

Senin, Alicia ;

Angona, Anna ;

Gomez, Montse ;

Vicente, Vicente ;

Cervantes, Francisco ;

Bellosillo, Beatriz ;

Besses, Carles .

ANNALS OF HEMATOLOGY, 2014, 93 (12) :2037-2043

[3] Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera [J].

Alvarez-Larran, Alberto ;

Pereira, Arturo ;

Cervantes, Francisco ;

Arellano-Rodrigo, Eduardo ;

Hernandez-Boluda, Juan-Carlos ;

Ferrer-Marin, Francisca ;

Angona, Anna ;

Gomez, Montse ;

Muina, Begona ;

Guillen, Helga ;

Teruel, Anabel ;

Bellosillo, Beatriz ;

Burgaleta, Carmen ;

Vicente, Vicente ;

Besses, Carles .

BLOOD, 2012, 119 (06) :1363-1369

[4] Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet [J].

Barbuil, Tiziano ;

Tefferi, Ayalew ;

Vannucchi, Alessandro M. ;

Passamonti, Francesco ;

Silvers, Richard T. ;

Hoffman, Ronald ;

Verstovsek, Srdan ;

Mesa, Ruben ;

Kiladjian, Jean-Jacques ;

Hehlmann, Rudiger ;

Reiter, Andreas ;

Cervantes, Francisco ;

Harrison, Claire ;

Mc Mullin, Mary Frances ;

Hasselbalch, Hans Carl ;

Koschmieder, Steffen ;

Marchetti, Monia ;

Bacigalupo, Andrea ;

Finazzil, Guido ;

Kroeger, Nicolaus ;

Griesshammer, Martin ;

Birgegard, Gunnar ;

Barosi, Giovanni .

LEUKEMIA, 2018, 32 (05) :1057-1069

[5] Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project [J].

Barosi, Giovanni ;

Mesa, Ruben ;

Finazzi, Guido ;

Harrison, Claire ;

Kiladjian, Jean-Jacques ;

Lengfelder, Eva ;

McMullin, Mary F. ;

Passamonti, Francesco ;

Vannucchi, Alessandro M. ;

Besses, Carlos ;

Gisslinger, Heinz ;

Samuelsson, Jan ;

Verstovsek, Srdan ;

Hoffman, Ronald ;

Pardanani, Animesh ;

Cervantes, Francisco ;

Tefferi, Ayalew ;

Barbui, Tiziano .

BLOOD, 2013, 121 (23) :4778-4781

[6] Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study [J].

Birgegard, Gunnar ;

Folkvaljon, Folke ;

Garmo, Hans ;

Holmberg, Lars ;

Besses, Carlos ;

Griesshammer, Martin ;

Gugliotta, Luigi ;

Wu, Jingyang ;

Achenbach, Heinrich ;

Kiladjian, Jean-Jacques ;

Harrison, Claire N. .

LEUKEMIA RESEARCH, 2018, 74 :105-109

[7] Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms [J].

Bjorkholm, Magnus ;

Derolf, Asa R. ;

Hultcrantz, Malin ;

Kristinsson, Sigurdur Y. ;

Ekstrand, Charlotta ;

Goldin, Lynn R. ;

Andreasson, Bjorn ;

Birgegard, Gunnar ;

Linder, Olle ;

Malm, Claes ;

Markevarn, Berit ;

Nilsson, Lars ;

Samuelsson, Jan ;

Granath, Fredrik ;

Landgren, Ola .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2410-2415

[8] Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera [J].

Casu, Carla ;

Oikonomidou, Paraskevi Rea ;

Chen, Huiyong ;

Nandi, Vijay ;

Ginzburg, Yelena ;

Prasad, Princy ;

Fleming, Robert E. ;

Shah, Yatrik M. ;

Valore, Erika V. ;

Nemeth, Elizabeta ;

Ganz, Tomas ;

MacDonald, Brian ;

Rivella, Stefano .

BLOOD, 2016, 128 (02) :265-276

[9] Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors [J].

Cerquozzi, S. ;

Tefferi, A. .

BLOOD CANCER JOURNAL, 2015, 5 :e366-e366

[10] Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study [J].

Finazzi, G ;

Caruso, V ;

Marchioli, R ;

Capnist, G ;

Chisesi, T ;

Finelli, C ;

Gugliotta, L ;

Landolfi, R ;

Kutti, J ;

Gisslinger, H ;

Marilus, R ;

Patrono, C ;

Pogliani, EM ;

Randi, ML ;

Villegas, A ;

Tognoni, G ;

Barbui, T .

BLOOD, 2005, 105 (07) :2664-2670

← 1 2 3 4 5 →